Emerging anticoagulants for the treatment of venous thromboembolism

Thrombosis and Haemostasis

Volumn 96, Issue 3, 2006, Pages 274-284

  Weitz, Jeffrey I ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Coagulation inhibitors; Deep vein thrombosis; Heparins glycosaminoglycans; Pulmonary embolism

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTIDOTE; ANTIVITAMIN K; APIXABAN; AZD 0837; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEMATOLOGIC AGENT; HEPARIN; IDRAPARINUX; LONG ACTING DRUG; LOW MOLECULAR WEIGHT HEPARIN; LY 517717; MELAGATRAN; PLACEBO; PROTAMINE SULFATE; RIVAROXABAN; SSR 126517E; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; YM 150;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG STRUCTURE; HEPARIN INDUCED THROMBOCYTOPENIA; HEPATORENAL SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LUNG EMBOLISM; NONHUMAN; OSTEOPOROSIS; PHLEBITIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK REDUCTION; URTICARIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; GLYCOSAMINOGLYCANS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MODELS, CHEMICAL; OLIGOSACCHARIDES; POLYSACCHARIDES; POSTPHLEBITIC SYNDROME; PULMONARY EMBOLISM; THROMBOEMBOLISM; VENOUS THROMBOSIS; VITAMIN K; WARFARIN;

EID: 33748590510     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-05-0234     Document Type: Review

References (67)

1. Lilienfeld DE, Chan E, Ehland J, et al. Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest 1990; 98: 1067-72.
2. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004; 164: 17-26.
3. Weitz JI. Low-molecular-weight heparins. N Eng] J Med 1997; 337: 688-98.
4. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-81.
5. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334: 682-7.
6. O'Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999; 159: 2298-304.
7. Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130: 789-99.
8. Harrison L, McGinnis J, Crowther M, et al. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998; 158: 2001-3.
9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
10. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 204S-33S.
11. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
12. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-33.
13. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
14. Keaton C. Long-term management of patients after venous thromboemlism. Circulation 2004; 110 (9 Suppl 1): I10-8.
15. Petitou M, Duchaussoy P, Herbert JM, et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28: 393-402.
16. Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest 2003; 124 (6 Suppl): 364S-70S.
17. Wiebe EM, Stafford AR, Fredenburgh JC, et al. Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. J Biol Chem 2003; 278: 35767-74.
18. Paolucci F, Frasa H, Van Aarle F, et al. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Clin Lab 2003; 49: 451-60.
19. Linkins LA, Julian JA, Rischke J, et al. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002; 107: 241-4.
20. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fandaparinux or enoxaparin. Blood 2005; 106: 3791-6.
21. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 1999; 5: 259-66.
22. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005; 105: 139-44.
23. Koo KH, Kovacs MJ. Fondaparinux: a potential new therapy for HIT. Hematology 2005; 10: 271-5.
24. Harenberg J, Jorg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004; 89: 1017-8.
25. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest 2005; 127 (2 Suppl): 1S-8S.
26. Lagrange F, Vergnes C, Bran JL, et al. Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002; 87: 831-5.
27. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med 2004; 350: 1914-5.
28. Koopman MM, Buller HR. Short- and long-acting synthetic pentasaccharides. J Intern Med 2003; 254: 335-42.
29. No authors listed. Idraparinux sodium: SANORG 34006, SR 34006. Drugs R D 2004; 5: 164-5.
30. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agents BAY59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-21.
31. Kubitz D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol 2005; 78: 412-21.
32. Turpie AG, Fisher WD, Bauer KA, et al. BAY59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005; 3: 2479-86.
33. Eriksson BI, Borris L, Dahl OE, et al. Oral direct factor Xa inhibition with BAY59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 121-8.
34. Eriksson BI, Borris L, Dahl OE, et al. Prevention of venous thromboembolism after total hip replacement with once-daily BAY59-7939 - an oral direct factor Xa inhibitor. Blood 2005; 106: 86a (Abstract #280).
35. Eriksson BI, Turpie AGG, Lassen MR, et al. YM 150, an oral direct factor Xa inhibitor, as prophylaxis for venous thromboembolism in patients with elective primary hip replacement surgery. A dose escalation study. Blood 2005; 106: 530a (Abstract #1865).
36. Agnelli G, Haas SK, Krueger KA, et al. A phase II study of the safety and efficacy of a novel oral fXa inhibitor (LY517717) for the prevention of venous thromboembolism following TKR and THR. Blood 2005; 106: 85a (Abstract #278).
37. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
38. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59: 35-43.
39. Bredberg E, Andersson TB, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003; 42: 765-77.
40. Eriksson UG, Johansson S, Attman PO, et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran, Clin Pharmacokinet 2003; 42: 743-53.
41. Johansson LC, Frisson L, Logren U, et al. Influence of age on the pharmacokinefics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinct 2003; 42: 381-92.
42. Lee WM, Larrey D, Olsson I, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28: 351-70.
43. McRae SJ, Ginsberg JS. New anticoagulants for venous thromboembolic disease. Curr Opin Cardiol 2005; 20: 502-8.
44. Levi M. New antithrombotics in the treatment of thromboembolic disease. Eur J Intern Med 2005; 16: 230-7.
45. Gustafsson D. Oral direct thrombin inhibitors in clinical development. J Intern Med 2003; 254: 322-34.
46. Mungall D. BIBR-1048 Boehringer Ingelheim. Curr Opin Investig Drugs 2002; 3: 905-7.
47. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-63.
48. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004; 2: 1573-80.
49. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-11.
50. Matziolis G, Perka C, Disch A, et al. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 2003; 73: 370-9.
51. Handschin AE, Trentz OA, Hoerstrup SP, et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 2005; 92: 177-83.
52. Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Contact Dermatitis 2003; 49: 276-80.
53. Jappe U, Juschka U, Kuner N, et al. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. Contact Dermatitis 2004; 51: 67-72.
54. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 867-73.
55. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-02.
56. PERSIST Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004; 2: 47-53.
57. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. J Am Med Assoc 2005; 293: 681-9.
58. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-21.
59. Diener HC; Executive Steering Committee on behalf of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006; 21: 279-93.
60. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-4.
61. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124: 653-8.
62. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse effects after use of recombinant human coagulation factor VIIa. J Am Med Assoc 2006; 295: 293-8.
63. Sinha U, Ku P, Malinowski J, et al. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur J Pharmacol 2000; 395: 51-9.
64. Fager G, Cullberg M, Eriksson-Lepkowska M, et al. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur J Clin Pharmacol 2003; 59: 283-9.
65. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-35.
66. Lee AY, Levine MN, Baker RI, et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
67. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-9.